UAB’s Director Of Infectious Diseases Warns Caution Around COVID-19 Vaccines In Trial
Dr. Jeanne Marrazzo speaks during a press conference September 3, 2020.
The director of infectious diseases at the University of Alabama at Birmingham says right now she would not take one of the COVID-19 vaccines currently in phase three clinical trials across the country.
During a press conference Thursday, Dr. Jeanne Marrazzo addressed the Centers for Disease Control’s announcement that a vaccine could be ready by the end of October. She said the vaccines have been fast-tracked and not much is known about their long term effects or success rates.
“Yes, I know there’s urgency, but we should not sacrifice our convenience for the rush to get a product that we just don’t know is really truly safe,” Marrazzo said. “We deserve the best. We deserve better. I mean people have been through hell with this thing.”
Efficacy trials, or better known as phase three trials, help determine if a vaccine works. In the case of COVID-19, for a phase three trial to be successful it must show that the vaccine reduces the number of actual infections in people and that participants are able to make antibodies against the virus over time.
But now, Marrazzo said, those efficacy standards may change with the release of data from a vaccine trial in the United Kingdom earlier this week.
“My big concern about this timeline that’s now out there is that not only do we not have the kind of evidence for efficacy, yet. Yet. I’m saying yet because maybe they know something I don’t know. That’s always possible,” Marrazzo said. “But do we really have confidence that we can go out there and vaccinate everybody safely without knowing the longer-term benefits or side effects of this vaccine?”
Marrazzo said she is also concerned that there is not enough information yet about long-lasting immunity to COVID-19, especially given recent reports of people being reinfected with the virus. She noted that the vaccines are based on a totally new technology.
“We have never had a messenger RNA vaccine in a human population before these trials,” Marrazzo said. “We think it’s safe, but we don’t know.”
She added that vaccines can have serious side effects. Marrazzo said phase three trials typically follow participants for at least a year, if not longer, to track possible side effects. If a vaccine is released in late October, it would have only been studied in humans for eight months – at most.
“We need iron-clad proof and assurance to the extent that anybody can get it in any vaccine study or any medical study that whatever product we make widely available to our citizens is as safe and effective as humanly possible,” Marrazzo said. “We are not there, right now. There’s no way I have seen, myself, and I know that most experts have seen enough data to feel like not only today there’s something to roll out but in seven short weeks … that there would be something to roll out.”
Marrazzo said ultimately the decision to get the vaccine is a risk-benefit analysis, but she will not get one unless it is backed by the Advisory Committee on Immunization Practices. Meanwhile, Marrazzo said she plans on volunteering for a vaccine clinical trial.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
European allies step up plans for Ukraine stabilization, with U.S. attending meeting
The force is expected to provide logistical and training experts to help reconstitute Ukraine's armed forces, secure Ukraine's skies and the Black Sea.
Protesters and federal agents clash during raid at Southern California farm
A confrontation erupted Thursday between protesters and federal officials carrying out a raid, with authorities throwing canisters to disperse the crowd.
Since COVID, threats to local school officials have nearly tripled, research finds
Researchers at Princeton University say some instances corresponded with national attacks on DEI initiatives as well as on LGBTQ+ policies and that the targets held a variety of political views.
UNAIDS report warns HIV progress at risk as U.S. funding cuts take hold
The UNAIDS annual report warns that Trump era HIV funding cuts could lead to 6 million more infections and 4 million deaths by 2029 — as low-income countries struggle to fill the gap.
Brazil’s Lula warns of 50% tariffs on U.S. goods after Trump trade threat
Brazil's President Lula is firing back at Trump's 50% tariff threat — saying Brazil is ready to match any U.S. import taxes, dollar for dollar.
Thousands celebrate baby hippo Moo Deng’s first birthday at a Thailand zoo
The Khao Kheow Open Zoo was overrun with Moo Deng fans on the first of four days of activities marking the birthday of the adorable social media sensation.
